Celera Sued Over Plans to Sell to Quest | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The New Orleans Employees Retirement System is suing Celera, alleging its plan to sell the company to Quest Diagnostics for $671 million undervalues the company.

Along with Celera, its CEO, Kathy Ordoñez, and its board of directors are named as defendants in the lawsuit filed in Delaware Chancery Court. Quest and its wholly owned subsidiary, Spark Acquisition, are also named as defendants.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.